Recombinant activated human factor VII (rFVIIa) is a hemostatic agent principally licensed to treat bleeding episodes and perioperative management in hemophilia A or B adults and children with inhibitors and adults with acquired hemophilia, congenital factor VII (FVII) deficiency, and Glanzmann's thrombasthenia. This evidence concerns the gene F7 and hemophilia A.